Skip to Main content Skip to Navigation
Journal articles

Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.

Abstract : Clinical-grade mesenchymal stromal cells (MSCs) are usually expanded from bone marrow (BMMSCs) or adipose tissue (ADSCs) using processes mainly differing in the use of fetal calf serum (FCS) or human platelet lysate (PL). We aimed to compare immune modulatory properties of clinical-grade MSCs using a combination of fully standardized in vitro assays. BMMSCs expanded with FCS (BMMSC-FCS) or PL (BMMSC-PL), and ADSC-PL were analyzed in quantitative phenotypic and functional experiments, including their capacity to inhibit the proliferation of T, B, and NK cells. The molecular mechanisms supporting T-cell inhibition were investigated. These parameters were also evaluated after pre-stimulation of MSCs with inflammatory cytokines. BMMSC-FCS, BMMSC-PL, and ADSC-PL displayed significant differences in expression of immunosuppressive and adhesion molecules. Standardized functional assays revealed that resting MSCs inhibited proliferation of T and NK cells, but not B cells. ADSC-PL were the most potent in inhibiting T-cell growth, a property ascribed to interferon-γ-dependent indoleamine 2,3-dioxygenase activity. MSCs did not stimulate allogeneic T cell proliferation but were efficiently lysed by activated NK cells. The systematic use of quantitative and reproducible validation techniques highlights differences in immunological properties of MSCs produced using various clinical-grade processes. ADSC-PL emerge as a promising candidate for future clinical trials.
Document type :
Journal articles
Complete list of metadatas

Cited literature [51 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00799812
Contributor : Cédric Ménard <>
Submitted on : Tuesday, February 25, 2014 - 7:00:05 AM
Last modification on : Monday, March 23, 2020 - 11:46:16 AM
Long-term archiving on: : Sunday, May 25, 2014 - 10:35:48 AM

Files

inserm-00799812_edited.pdf
Files produced by the author(s)

Identifiers

Citation

Cedric Menard, Luciano Pacelli, Giulio Bassi, Joelle Dulong, Francesco Bifari, et al.. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.. Stem Cells and Development, Mary Ann Liebert, 2013, 22 (12), pp.1789-801. ⟨10.1089/scd.2012.0594⟩. ⟨inserm-00799812⟩

Share

Metrics

Record views

944

Files downloads

2489